National consortium to study the threats of new SARS-CoV-2 variants 15 January 2021A new national research project to study the effects of emerging mutations in SARS-CoV-2 is launched today [15 Jan]. The £2.5 million UK Research and Innovation (UKRI)-funded ‘G2P-UK’ National Virology Consortium will study how mutations in the virus affect key outcomes such as how transmissible it is, the severity of COVID-19 it causes, and the effectiveness of vaccines and treatments.
Increased risk of domestic violence over Christmas10 December 2020Domestic violence and health experts from the University of Bristol are urging men in Bristol, South Gloucestershire, North Somerset, Somerset, Wiltshire and Gwent (South Wales) to get in touch if they are worried about being abusive or controlling in their relationships with women.
Analysis finds four repurposed antiviral drugs have little or no effect on patients hospitalised for COVID-194 December 2020Repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir and interferon - to treat COVID-19 appear to have little or no effect on patients hospitalised for the disease, in terms of overall mortality, initiation of ventilation and duration of hospital stay. The interim findings from the WHO Solidarity trial, published in the New England Journal of Medicine (NEJM), followed 11,266 adults at 405 hospitals in 30 countries.
The COVID-19 pandemic: in a world of fake news, why science matters2 December 2020The COVID-19 pandemic raises important questions about the role of life sciences in society and if the voices of scientists are now less audible or less important, is this a problem and how can this be addressed? This question will be one of many tackled by a panel, including Nobel Prize-winning biologist, Sir Paul Nurse and Bristol Mayor, Marvin Rees, for a live online event to celebrate the launch of the University of Bristol's Faculty of Life Sciences.
New study to investigate COVID-19 and misinformation1 December 2020Researchers at the University of Bristol and King's College London are leading a major new study to investigate COVID-19 perceptions and misperceptions, lockdown compliance and vaccine hesitancy.
World's first research programme to identify scarring gene launched26 November 2020A world-leading £1.5 million research programme that aims to achieve scar free healing within a generation has been launched today [26 November] by The Scar Free Foundation, the only medical research charity which focuses solely on scarring. The five-year research study led by the University of Bristol will identify the gene(s) that causes scarring and inform future treatments.
Spread Germ Defence, not the virus!25 November 2020With Covid-19 infections still high and people preparing for Christmas gatherings, it is vitally important to try to reduce the spread of infection in people's homes as this is where infections are now most likely to be transmitted. Research suggests people who follow the advice from Germ Defence are less likely to catch flu or other viruses and less likely to pass it on to members of their household.
Young people's anxiety levels doubled during first COVID-19 lockdown, says study 24 November 2020The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol. The study, using Bristol’s Children of the 90s questionnaire data, showed that young people (27-29 years) reported higher levels of anxiety during the early phases of the pandemic in the first national lockdown and this was higher than their parents.
Rapid point-of-care testing during and after COVID-19 – how widely should it be used?17 November 2020Even before the COVID-19 pandemic, the point-of-care testing industry was investing millions of pounds to develop rapid tests to tell us the cause of respiratory infections. The pandemic has accelerated this process. In an editorial published in the British Journal of General Practice today [17 November], researchers from the University of Bristol’s Centre for Academic Primary Care ask if we know enough about these tests to merit their widespread use in primary care.
Accuracy of rapid covid test may be lower than previously suggested12 November 2020The accuracy of a rapid finger-prick antibody test for SARS-CoV-2, the virus responsible for Covid-19 infection, may be considerably lower than previously suggested, finds a study led by scientists from Public Health England and the Universities of Bristol, Cambridge and Warwick published in The BMJ.
Interactive virtual reality emerges as a new tool for drug design against COVID-1912 November 2020Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus – and enable researchers to share models and collaborate in new ways. The innovative tool, created by University of Bristol researchers, and published in the Journal of Chemical Information and Modeling, will help scientists around the world identify anti-viral drug leads more rapidly.
Bristol COVID-19 experts to answer your questions4 November 2020COVID-19 has had an enormous impact on nearly every aspect of our everyday lives. In response, researchers from the University of Bristol are working together and with partners around the world to understand the virus, develop a vaccine and help bring an end to the pandemic.
What’s the STORY of infectious diseases in the UK? 26 October 2020A study looking at how children's immune systems respond to COVID-19, and to vaccines for other infectious diseases, is asking children under the age of 20 who live in the Bristol area to consider taking part. The research project is being run by the Bristol Children’s Vaccine Centre (BCVC) at Bristol Medical School, and the Oxford Vaccine Group which is part of the University of Oxford.
Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds 22 October 2020The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) now undergoing Phase III clinical trials, has already undergone rigorous testing to ensure the highest standards of quality and safety. Now a team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team. This novel analysis provides even greater clarity and detail about how the vaccine successfully provokes a strong immune response.